23:25 , Jan 9, 2018 |  BioCentury  |  Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
17:11 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

Ampio's Ampion meets in latest Phase III OA trial

Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) said Ampion met the primary endpoint in the Phase III AP-003-C trial to treat severe osteoarthritis (OA) of the knee. Ampio hopes to meet with FDA next quarter, after which the...
22:47 , Dec 14, 2017 |  BC Extra  |  Clinical News

Latest Phase III OA readout boosts Ampio shares

Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) added $0.58 (33%) to $2.33 on Thursday after reporting that Ampion met the primary endpoint in the Phase III AP-003-C trial to treat severe osteoarthritis of the knee. Ampio hopes to...
21:01 , May 17, 2017 |  BC Week In Review  |  Clinical News

Ampio starts pivotal trial of Ampion for OA of the knee

Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) began a blinded, placebo-controlled, pivotal trial evaluating single intra-articular injections of Ampion to treat Kellgren-Lawrence (KL) grade IV osteoarthritis (OA) of the knee. Under FDA guidance, the 12-week trial will evaluate response...
19:33 , Dec 2, 2016 |  BC Week In Review  |  Clinical News

Ampion: Preliminary Ph I data

Preliminary data from the double-blind, placebo-controlled, U.S. Phase I AP-011 trial in 15 patients showed that a single intra-articular injection of up to 3 mL Ampion was well tolerated with no serious adverse events reported....
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

Ampion: Phase III data

Top-line data from the double-blind, U.S. Phase III PIVOT trial in 480 patients with pain due to OA of the knee showed that a single 4 mL intra-articular injection of Ampion missed the primary endpoint...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big caps...
01:06 , Jul 1, 2016 |  BC Extra  |  Clinical News

Ampio sags after OA candidate's latest miss

Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) fell $2.03 (61%) to $1.29 on Thursday after Ampion missed the primary endpoint of significantly reducing WOMAC-A pain subscale scores vs. saline control in the Phase III PIVOT trial to treat...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Clinical News

Ampion: Completed Phase III enrollment

Ampio completed enrollment of 480 patients in the double-blind, placebo-controlled, U.S. Phase III PIVOT trial evaluating single 4 mL intra-articular injections of Ampion. Ampio has an SPA from FDA for the trial (see BioCentury, Sept....